Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

Cortelazzo, 2012, Mantle cell lymphoma, Crit Rev Oncol Hematol, 82, 78, 10.1016/j.critrevonc.2011.05.001

Herrmann, 2009, Improvement of overall survival in advanced stage mantle cell lymphoma, J Clin Oncol, 27, 511, 10.1200/JCO.2008.16.8435

Dreyling, 2014, Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 25, iii83, 10.1093/annonc/mdu264

Ferrero, 2013, The current therapeutic scenario for relapsed mantle cell lymphoma, Curr Opin Oncol, 25, 452, 10.1097/CCO.0b013e328363df0b

McKay, 2012, Guidelines for the investigation and management of mantle cell lymphoma, Br J Haematol, 159, 405, 10.1111/bjh.12046

Khan, 2012, Colonel Bruton's kinase defined the molecular basis of X-linked agammaglobulinemia, the first primary immunodeficiency, J Immunol, 188, 2933, 10.4049/jimmunol.1200490

Buggy, 2012, Bruton tyrosine kinase (BTK) and its role in B-cell malignancy, Int Rev Immunol, 31, 119, 10.3109/08830185.2012.664797

Cinar, 2013, Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis, Leuk Res, 37, 1271, 10.1016/j.leukres.2013.07.028

de Rooij, 2012, The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia, Blood, 119, 2590, 10.1182/blood-2011-11-390989

Herman, 2011, Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765, Blood, 117, 6287, 10.1182/blood-2011-01-328484

Honigberg, 2010, The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy, Proc Natl Acad Sci USA, 107, 13075, 10.1073/pnas.1004594107

Ponader, 2012, The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo, Blood, 119, 1182, 10.1182/blood-2011-10-386417

Wang, 2013, Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma, N Engl J Med, 369, 507, 10.1056/NEJMoa1306220

Wang, 2015, Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results, Blood, 126, 739, 10.1182/blood-2015-03-635326

Wang, 2014, Efficacy and safety of single-agent ibrutinib in patients with mantle cell lymphoma who progressed after bortezomib therapy, Blood, 124, 4471, 10.1182/blood.V124.21.4471.4471

Rudelius, 2006, Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma, Blood, 108, 1668, 10.1182/blood-2006-04-015586

Witzig, 2005, Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma, J Clin Oncol, 23, 5347, 10.1200/JCO.2005.13.466

Ansell, 2008, Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group, Cancer, 113, 508, 10.1002/cncr.23580

Hess, 2009, Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma, J Clin Oncol, 27, 3822, 10.1200/JCO.2008.20.7977

Cheson, 2007, Revised response criteria for malignant lymphoma, J Clin Oncol, 25, 579, 10.1200/JCO.2006.09.2403

Oken, 1982, Toxicity and response criteria of the Eastern Cooperative Oncology Group, Am J Clin Oncol, 5, 649, 10.1097/00000421-198212000-00014

Hoster, 2008, A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma, Blood, 111, 558, 10.1182/blood-2007-06-095331

Hlubocky, 2013, The development and validation of a measure of health-related quality of life for non-Hodgkin's lymphoma: the Functional Assessment of Cancer Therapy—Lymphoma (FACT-Lym), Lymphoma, 2013

Carter, 2008, Validation of the Functional Assessment of Therapy—Lymphoma (FACT-LYM) in patients with relapsed/refractory mantle cell lymphoma, Blood, 112, 828, 10.1182/blood.V112.11.2376.2376

Cella, 2005, Development of a measure of health-related quality of life for non-Hodgkin's lymphoma clinical research: the Functional Assessment of Cancer Therapy—Lymphoma (FACT-Lym), Blood, 106, 750, 10.1182/blood.V106.11.750.750

Fisher, 2006, Multicenter phase 2 study of bortezomib in patients with relapsed and refractory mantle cell lymphoma, J Clin Oncol, 24, 4867, 10.1200/JCO.2006.07.9665

Goy, 2013, Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study, J Clin Oncol, 31, 3688, 10.1200/JCO.2013.49.2835

Dreyling, 2013, A phase III study of ibrutinib in combination with bendamustine and rituximab (BR) in elderly patients with newly diagnosed mantle cell lymphoma (MCL), Hematol Oncol, 31, 137